[at MarketWatch] – Growing optimism for Gilead Sciences Inc.’s hepatitis C treatment, Sovaldi, vaults shares of the biotechnology company to the top of the S&P 500.
Read more on this.
Gilead Sciences Inc. (GILD), … [visit site to read more]
Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500
January 16, 2014 at 15:09 PM EST
[at MarketWatch] – Growing optimism for Gilead Sciences Inc.’s hepatitis C treatment, Sovaldi, vaults shares of the biotechnology company to the top of the S&P 500. Read more on this. Gilead Sciences . . . → Read More: Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500
